Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials
نویسندگان
چکیده
منابع مشابه
Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate
Objective Atypical meningioma is rare tumor and there is no accurate guide line for optimal treatment. This retrospective study analyzed the prognostic factors, the effect of different methods of treatments and the behavior of atypical meningioma. Methods Thirty six patients were diagnosed as atypical meningioma, among 273 patients who were given a diagnosis of meningioma in the period of 200...
متن کاملCombining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.
BACKGROUND The use of auxiliary endpoints may provide efficiencies for clinical trial design, but such endpoints may not have intrinsic clinical relevance or clear linkage to more meaningful endpoints. The purpose of this study was to generate a novel endpoint that considers both overall survival (OS) and earlier events such as progression-free survival (PFS) and determine whether such an endpo...
متن کاملEstimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer.
OBJECTIVES In clinical trials of new cancer drugs, reliable data for progression-free survival will often become available far sooner than reliable data for overall survival. The aim of this study was to determine how many months it would be expected that any given new drug for metastatic breast or colorectal cancer will add to overall survival times given that the number of months the drug add...
متن کاملOngoing Clinical Trials Ot-01. Is Surgery at Progression a Prognostic Marker for Improved 6-month Progression-free Survival or Overall Survival for Patients with Recurrent Glioblastoma?
Historically, the North American Brain Tumor Consortium (NABTC) has used 6-month progression-free survival (PFS6) as the primary endpoint of Phase II clinical trials for recurrent glioma. Measurable disease has not been required and patients with recent surgeries have been eligible. In some trials, a subset of patients has received the trial agent before surgery to allow for the assessment of t...
متن کاملProgression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
BACKGROUND The aim of this study was to determine correlations between progression-free survival (PFS) and the objective response rate (ORR) with overall survival (OS) in glioblastoma and to evaluate their potential use as surrogates for OS. METHOD Published glioblastoma trials reporting OS and ORR and/or PFS with sufficient detail were included in correlative analyses using weighted linear r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA Network Open
سال: 2020
ISSN: 2574-3805
DOI: 10.1001/jamanetworkopen.2020.11809